Gene Regulatory and Clinical Effects of Interferon β in Patients with Metastatic Melanoma: A Phase II Trial
- 1 May 2011
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Interferon & Cytokine Research
- Vol. 31 (5), 433-440
- https://doi.org/10.1089/jir.2010.0054
Abstract
Interferon (IFN)-β in preclinical studies, compared to IFN-α2, bound with higher affinity to its receptor, induced to higher levels of IFN-stimulated gene products, induced more apoptosis in melanoma cells, and had antitumor effects against melanoma. A maximally tolerated dose of 12 × 106 international units/m2 after 2 weeks subcutaneously daily with dose escalation to 18 × 106 international units/m2 was thus used in a phase II trial of IFN-β1a in cutaneous metastatic melanoma (n = 17) and uveal melanoma (n = 4). It resulted in expected but reversible drug-related severe (grade 3) adverse events in 13/21 patients; anorexia and fatigue were mostly of mild or moderate severity and infrequently needed dose reduction. Although a single patient had a sustained regression, overall IFN-β1a did not have clinical benefit (response rate <10%; median progression-free survival 1.8 months). Effective and potent induction in peripheral blood cells and into serum of products of IFN-stimulated genes such as the pro-apoptotic cytokine, TRAIL, and the immunomodulatory and anti-angiogenic chemokines, CXCL10 and CCL8, confirmed gene regulatory actions. To probe further anti-angiogenic mechanisms, both VEGF-A and CXCL-5 were assessed; compared to before treatment, both proteins decreased. Continued improvements in understanding of antitumor mechanisms will enhance usefulness of IFNs for nodal or distant metastases from melanoma.Keywords
This publication has 61 references indexed in Scilit:
- Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology, 2009
- Heterogeneous, Longitudinally Stable Molecular Signatures in Response to Interferon-βAnnals of the New York Academy of Sciences, 2009
- Following TRAIL’s path in the immune systemImmunology, 2009
- A stress-responsive RNA switch regulates VEGFA expressionNature, 2009
- Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative RegimensJournal of Clinical Oncology, 2008
- Directing cancer cells to self-destruct with pro-apoptotic receptor agonistsNature Reviews Drug Discovery, 2008
- Adjuvant therapy of melanoma with interferon: lessons of the past decadeJournal of Translational Medicine, 2008
- Gene Expression Profiling Reveals Similarities between theIn vitroandIn vivoResponses of Immune Effector Cells to IFN-αClinical Cancer Research, 2008
- Multiplex Analysis of Serum Cytokines in Melanoma Patients Treated with Interferon-α2bClinical Cancer Research, 2007
- Interferons induce proteolytic degradation of TRAILR4Biochemical and Biophysical Research Communications, 2005